NYP/Columbia was among the first to offer patients access to Heartmate 3, the newest LVAD technology, in a clinical trial testing it against current standard of treatment, the Heart Mate II.
In a randomized study reported in New England Journal of Medicine and presented at American Heart Association in November 2016, lead investigator Yoshifumi Naka, MD, PhD, reported fewer complications with the Heartmate 3, noting a marked improvement over Heartmate II.
Read More